VivoSeq
Oncology

Stage IV Ovarian Epithelial Cancer

0

Pipeline Programs↗

0

Active Trials↗

1

Companies Involved↗

Stage IV Ovarian Epithelial Cancer is an early-stage landscape with 0 programs across 1 company. The most active players are Gynecologic Oncology Group.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

67/100

Attrition Rate

25/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

G

Gynecologic Oncology Group

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

8

clinical trials

Completed4 · 50%
Unknown status2 · 25%
Terminated2 · 25%

Clinical Trials

Trial Activity

8 trials

High-Dose Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer That Has Been Removed During Surgery
Completed·EEBMT Solid Tumors Working Party·Phase 3·NCT00004921
Paclitaxel Plus Carboplatin With or Without Topotecan in Treating Patients With Stage IIB, Stage III, or Stage IV Ovarian Epithelial Cancer
Completed·AAGO Study Group·Phase 3·NCT00006454
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer
Completed·UUniversity of Maryland, Baltimore·Phase 2·NCT00003413·32 enrolled
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Completed·GGynecologic Oncology Group·Phase 3·NCT00011986·4,312 enrolled
Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer
Terminated·GGynecologic Oncology Group·Phase 2·NCT00003386
Rebeccamycin Analogue in Treating Patients With Refractory Stage III or Stage IV Ovarian Epithelial Cancer
Terminated·NNorthwestern University·Phase 2·NCT00006262
Paclitaxel and Cisplatin as First-Line Treatment for Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer
Unknown status·RRussian Academy of Medical Sciences·Phase 2·NCT00964626·60 enrolled
Docetaxel and Oxaliplatin in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer
Unknown status·GERCOR - Multidisciplinary Oncology Cooperative Group·Phase 1/2·NCT00075543

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)